Using registries to monitor HIV pre-exposure prophylaxis safety in clinical settings

American Journal of Preventive Medicine

Volumn 44, Issue 1 SUPPL. 2, 2013, Pages

  Tilson, Hugh H ^a  

^a University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL PRACTICE; DRUG SAFETY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEALTH CARE DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; PRENATAL EXPOSURE; REGISTRATION; UNSPECIFIED SIDE EFFECT;

EID: 84871744140     PISSN: 07493797     EISSN: 18732607     Source Type: Journal    
DOI: 10.1016/j.amepre.2012.09.042     Document Type: Review

References (18)

1. Agency for Healthcare Research and Quality Registries for evaluating patient outcomes: a user's guide 2nd ed. 2010 effectivehealthcare.ahrq.gov/ index.cfm/search-for-guides-reviews-and-reports/?productid=531&pageaction= displayproduct
2. A.G. Hartzema, H.H. Tilson, K.A. Chan Pharmacoepidemiology and therapeutic risk management 1st ed. 2008 Harvey Whitney Books Cincinnati OH
3. IOM Ethical and scientific issues in studying the safety of approved drugs 2012 www.iom.edu/Reports/2012/Ethical-and-Scientific-Issues-in-Studying- the-Safety-of-Approved-Drugs.aspx
4. Food and Drug Administration, DHHS. Postmarketing reporting of adverse drug experiences. U.S. Code of Federal Regulations (CFR) 21: Section 314.80, 2012.
5. CDC National Program of Cancer Registries (NPCR) 2012 www.cdc.gov/cancer/npcr/
6. J.L. Salemi, J.P. Tanner, S. Block The relative contribution of data sources to a birth defects registry utilizing passive multisource ascertainment methods: does a smaller birth defects case ascertainment net lead to overall or disproportionate loss? J Registry Manag 36 1 2011 30 38
7. L.J. Koenig, C. Lyles, D.K. Smith Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: lessons learned from past trials and studies Am J Prev Med 44 1S2 2013 S91 S98
8. A.C. Readhead, D.E. Gordon, Z. Wang Transmitted antiretroviral drug resistance in New York State, 2006-2008: results from a new surveillance system PLoS One 7 8 2012 e40533
9. B.B. Simen, J.F. Simons, K.H. Hullsiek Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes J Infectious Dis 199 5 2009 693 701
10. J. Baeten, D. Donnell, P. Ndase Partners PrEP Study Team Antiretroviral prophylaxis for HIV prevention in heterosexual men and women N Engl J Med 367 5 2012 399 410
11. Mugo N, Celum C, Donnell D, et al. Pregnancy incidence and birth outcomes in a clinical trial of PrEP: Uganda and Kenya. Proceedings of the 19th conference on Retroviruses and Opportunistic Infections; 2012; Seattle WA.
12. Food and Drug Administration Truvada prescribing information label revision 2012 www.accessdata.fda.gov/drugsatfda-docs/label/2012/021752s031lbl. pdf
13. Antiretroviral Pregnancy Registry Antiretroviral Pregnancy Registry, interim report: 1 January 1989 through 31 January 2012 www.apregistry.com/forms/ interim-report.pdf
14. S. Le, P.O. Shafer, E. Bartfeld, R.S. Fisher An online diary for tracking epilepsy 1 Epilepsy Behav 22 4 2011 705 709
15. Food and Drug Administration FDA Amendments Act (FDAAA) of 2007: Section 909 2007 www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ FoodandDrugAdministrationAmendmentsActof2007/ucm095439.htm
16. Food and Drug Administration FDA's safe use initiative 2009 www.fda.gov/downloads/Drugs/DrugSafety/UCM188961.pdf
17. Food and Drug Administration Advances in FDA's safety program for marketed drugs 2012 www.fda.gov/downloads/Drugs/DrugSafety/UCM300946.pdf
18. S.E. Andrade, R.L. Davis, T.C. Cheetham Medication exposure in pregnancy risk evaluation program Matern Child Health J 16 7 2012 1349 1354